References
- 1. Ferlay, J., Soerjomataram, I., Ervik, M., et al. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. Retrieved March 3, 2016 from: http://globocan.iarc.fr
- 2. Global Cancer Facts & Figures 3rd Edition. Retrieved March 5, 2016 from http://www.cancer.org/acs/groups/content/@research/
- 3. Bussolati, G. & Sapino, A. (2012). Mucinous carcinoma and carcinoma with signet-ring-cell differentiation. In Lakhani S., Ellis I., Schnitt S., et al. (Eds.) WHO Classification of Tumours of the Breast 4th ed. (pp 60-61). Lyon: IARC Press.
- 4. Cao, A.Y., He, M., Liu, Z.B., Di, G.H., Wu, J., Lu, J.S., Liu, G.Y., Shen, Z.Z. & Shao, Z.M. (2012). Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol. Sep 19(9):3019-27. doi: 10.1245/s10434-012-2322-6. 19:3019–3027.
- 5. Bae, S.Y., Choi, M.Y., Cho, D.H., et al. (2011). Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 14:308–13. doi: 10.4048/jbc.2011.14.4.308.
- 6. Sahoo, S. & Shin, S.J. (2012). Special types of breast carcinoma: tubular carcinoma, mucinous carcinoma, cribriform carcinoma, invasive micropapillary carcinoma and medullary carcinoma. In Dabbs DJ. Breast pathology. (pp 536-572). Elsevie Saunder.
- 7. Kashiwagi, S., Onoda, N., Asano, Y., Kawajiri, H., Takashima, T., Ohsawa, M., et al. (2013). Clinical significance of the subclassification of 71 cases mucinous breast carcinoma. Springer plus. 2:481-86.
- 8. Corben, A.D. & Brogi, E. (2014) Mucinous carcinoma. In Hoda, S.A., Brogi, E., Koerner, F.C. & Rosen, PP. (Eds.) Rosen’s breast pathology–fourth edition. (pp 611-644). Philadelphia: Lippincott Williams & Wilkins.
- 9. Elston, C.W. & Ellis, I.O. (1991). Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19 (5): 403-10.
- 10. Hammond, M.E., Hayes, D.F., Allred, D.C., Dowsett, M., Hagerty, KL., Badve, S., et al. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. 134(7):e48-e72.
- 11. Dowsett, M., Nielsen, T.O., A’Hern, R., Bartlett, J., Coombes, C., Cuzick, J., Ellis, M. et al. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103(22):1656-1664.
- 12. Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H. et al. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi: 10.1200/JCO.2013.50.9984.
- 13. Di Saverio, S., Gutierrez, J. & Avisar, E. (2008). A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 111:541-547.
- 14. Sahoo, S. & Shin, S.J. (2012) Special types of breast carcinoma: tubular carcinoma, mucinous carcinoma, cribriform carcinoma, invasive micropapollary carcinoma and medullary carcinoma. In Dabbs DJ.(Eds) Breast pathology. (pp 536-572). Elsevier Saunders
- 15. Ishikawa, T., Hamaguchi, Y., Ichikawa, Y. et al. (2002). Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. Jpn J Clin Onc. 32:64-67.
- 16. Scopsi, L., Andreola, S., Pilotti, S., et al (1994). Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation. Am J Surg Pathol. 18:702-711.
- 17. Ranade, A., Batra, R., Sandhu, G., et al (2010). Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micro papillary pattern. J Clin Pathol. 63:1043-1047.
- 18. Diab, S.G., Clark, G.M., Osborne, C.K., et al (1999). Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 17:1442-1448
- 19. Fentiman, I.S., Millis, R.R., Smith, P., et al. (1997) Mucoid breast carcinomas: histology and prognosis. Br T Cancer. 75:1061-1065.
- 20. Gadre, S.A., Perkins, G.H., Sabin, A.A., et al. (2008) Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology. 53:545-553.
- 21. Slodkowska, E., Corben, A.D., Catalano, J.P., et al (2012). Pure mucinous carcinoma in women 40 years old or younger: clinicopathological and follow-up study. USCAP Meeting Vancouver Canada, March 2012.
- 22. Lacroix-Triki, M., Suarez, P.H., MacKay, A., et al. (2010). Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 222:282-298.
- 23. Park, S., Koo, J., Park, H.S., et al. (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol. 21:488-492.
- 24. Cho, L.C. & Hsu, Y.H. (2008) Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung I Med Sci. 24:227-232
- 25. Rauch, G.M., Kuerer, H.M., Scoggins, M.E., Fox, P.S., et al (2013). Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast byestrogen receptor status. Breast Cancer Res Treat 139:639–647. doi:10.1007/s10549-013-2598-7.
- 26. Lari, S.A. & Kuerer, H.M. (2011) Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2:232-261. doi:10.7150/jca.2.232.
- 27. Walker, R.A., Hanby, A., Pinder, S.E., et al.(2012) Current issues in diagnostic breast pathology. J Clin Pathol. 65:771-785
- 28. Allred, D.C., Bryant, J., Land, S., et al. (2002) Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res. Treat. 76 (Suppl. 1), (abstract 30).
- 29. Roka, S., Rodas, M., Taucher, S., et al. (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol. 30:243-247.
- 30. Wiechmann, L. & Kuerer, H.M. (2008). The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 112:2130–2142. doi:10.1002/cncr.23430.
- 31. Williams, K.E., Barnes, N.L.P., Cramer, A., Johnson, R., et al (2015) Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 26(5):1019-1025
- 32. Lohrisch, C. & Piccart, M. (2001) An overview of HER2. Semin Oncol. 28:3–31.
- 33. Latta, E.K., Tjan, S., Parkes, R.K. & O’Malley, F.P. (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 15:1318–25.
- 34. Borgquist, S., Zhou, W., Jirström, K., Amini, R.M., Sollie, T., Sørlie, T., et al (2015). The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.
- 35. Hoque A, Sneige N, Sahin AA. (2002). Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 11:587–590.
- 36. Bockstal MV., Lambein K., Denys H., Braems G. et al. (2014) Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. Virchows Arch. 465:275–289; doi 10.1007/s00428-014-1609-3